GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » Current Ratio

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Current Ratio : 0.50 (As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Innovus Pharmaceuticals's current ratio for the quarter that ended in Sep. 2019 was 0.50.

Innovus Pharmaceuticals has a current ratio of 0.50. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Innovus Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Innovus Pharmaceuticals's Current Ratio or its related term are showing as below:

INNV's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.9
* Ranked among companies with meaningful Current Ratio only.

Innovus Pharmaceuticals Current Ratio Historical Data

The historical data trend for Innovus Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals Current Ratio Chart

Innovus Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.17 0.58 0.72 0.68

Innovus Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.68 0.80 0.69 0.50

Competitive Comparison of Innovus Pharmaceuticals's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Innovus Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovus Pharmaceuticals's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innovus Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Innovus Pharmaceuticals's Current Ratio falls into.



Innovus Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Innovus Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Current Ratio (A: Dec. 2018 )=Total Current Assets (A: Dec. 2018 )/Total Current Liabilities (A: Dec. 2018 )
=5.016/7.353
=0.68

Innovus Pharmaceuticals's Current Ratio for the quarter that ended in Sep. 2019 is calculated as

Current Ratio (Q: Sep. 2019 )=Total Current Assets (Q: Sep. 2019 )/Total Current Liabilities (Q: Sep. 2019 )
=4.353/8.736
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovus Pharmaceuticals  (OTCPK:INNV) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Innovus Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
8845 Rehco Road, San Diego, CA, USA, 92121
Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.
Executives
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu director
Henry Jemil Esber director 38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz officer: EVP, CORPORATE DEVELOPMENT 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn officer: VP, CFO 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj director, officer: CHIEF EXECUTIVE OFFICER C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman officer: Chief Financial Officer ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown officer: See remarks 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew director 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness director, officer: Secretary 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack director, 10 percent owner, officer: President & CEO 175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111